Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update
Vivani Medical reported its second-quarter 2026 financial results, highlighting significant progress in its clinical development, including the successful dosing of all participants in its SLIM-1 Phase 1 trial for NPM-139, a semaglutide implant for chronic weight management. The company also announced a non-exclusive agreement …